SCHEDULE: D. E. Shaw & Co. Amends Sarepta Therapeutics Stake Disclosure
Beneficial Ownership Amendment
D. E. Shaw & Co., L.P. and David E. Shaw have filed an amended Schedule 13G, disclosing a 5.1% beneficial ownership in Sarepta Therapeutics, Inc. and correcting a prior omission.
Summary
- D. E. Shaw & Co., L.P. and David E. Shaw reported beneficial ownership of 5,059,912 shares of Sarepta Therapeutics, Inc. common stock.
- This represents 5.1% of the outstanding class of securities.
- The filing is an Amendment No. 1 to a Schedule 13G.
- The amendment was filed solely to include a Joint Filing Agreement dated July 25, 2025, which was previously omitted from the initial filing due to a technical issue with a third-party filing service.
- The reporting persons have shared voting power over 5,000,212 shares and shared dispositive power over 5,059,912 shares.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine compliance filing disclosing beneficial ownership and correcting a minor administrative omission.
Future Outlook
NA
Industry Context
This filing is a standard disclosure by an institutional investor, D. E. Shaw & Co., L.P., a prominent hedge fund, regarding its passive stake in a publicly traded biotechnology company, Sarepta Therapeutics. Such filings provide transparency on significant ownership positions in the market, which is a routine aspect of investment management and regulatory compliance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Filing Compliance Procedure | Inclusion of a Joint Filing Agreement to formalize the joint reporting of beneficial ownership by D. E. Shaw & Co., L.P. and David E. Shaw. | July 25, 2025 | Enhances transparency and ensures compliance with SEC reporting requirements for beneficial ownership. |
Stakeholder Impact
- Primarily impacts investors and regulatory bodies by providing updated and complete information on a significant ownership stake in Sarepta Therapeutics.
Key Dates
| Date | Description |
|---|---|
| August 1, 2024 | Date of Power of Attorney granted by David E. Shaw. |
| July 18, 2025 | Date of event which required the filing of the statement. |
| July 25, 2025 | Date of Joint Filing Agreement and the date the Schedule 13G Amendment was signed and filed. |
Keywords
Sarepta Therapeutics, D. E. Shaw, David E. Shaw, Schedule 13G, beneficial ownership, common stock, investment management, SEC filing, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.